Stay updated on CDX-0159 in Eosinophilic Esophagitis Clinical Trial
Sign up to get notified when there's something new on the CDX-0159 in Eosinophilic Esophagitis Clinical Trial page.

Latest updates to the CDX-0159 in Eosinophilic Esophagitis Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5 to reflect a newer page version. This appears to be a minor software/template update rather than a content change.SummaryDifference0.0%

- Check12 days agoChange DetectedThe study record now lists the intervention as CDX-0159 (barzolvolimab) administered subcutaneously as a Biological. Related entries such as 'Other Names' and administration details have been updated (dated 2026-05-27 and 2026-05-22).SummaryDifference0.5%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedPage revision label updated from v3.5.3 to v3.5.4. This indicates a minor update to the page's documentation.SummaryDifference0.0%

- Check40 days agoChange DetectedAdministrative updates were made to the study record: new entries for Certification/Extension First Posted on 2026-05-01 and Certification/Extension First Submitted on 2026-04-28, along with Certification/Extension Dates (2026-04). Older entries from 2026-01-29 and 2026-01 were removed.SummaryDifference0.4%

- Check47 days agoChange DetectedThe page’s footer release/version label was updated from Revision v3.5.2 to Revision v3.5.3.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to CDX-0159 in Eosinophilic Esophagitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CDX-0159 in Eosinophilic Esophagitis Clinical Trial page.